IMGO · Imago Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $13.45M | $9.68M | $4.77M | - | $3.58M | $3.35M |
| SG&A | $4.09M | $4.34M | $4.01M | - | $734.0K | $649.0K |
| Total Operating Expenses | $17.55M | $14.02M | $16.51M | - | $4.31M | $8.84M |
| D&A | - | - | $3.0K | - | - | - |
| Operating Income | ($17.55M) | ($14.02M) | ($7.15M) | - | ($11.72M) | ($4.00M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | - | - |
| Net Income | ($16.78M) | ($13.74M) | ($16.39M) | - | ($11.67M) | ($8.81M) |
| EPS - Basic | ($0.44) | ($8.13) | - | - | - | - |
| EPS - Diluted | ($0.50) | ($0.41) | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.29M | $22.77M | $8.26M | $11.23M | $85.21M | $19.27M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.90M | $2.58M | $3.33M | $3.46M | $1.91M | $1.96M |
| Current Assets | $182.04M | $192.57M | $208.98M | $221.30M | $234.60M | $82.64M |
| Total Assets | $186.46M | $196.11M | $212.45M | $224.79M | $237.28M | $85.19M |
| Current Liabilities | $13.84M | $8.77M | $12.93M | $10.09M | $8.91M | $6.39M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $172.62M | $187.34M | $199.51M | $214.69M | $228.36M | ($68.78M) |
| Retained Earnings | ($159.56M) | ($142.79M) | ($129.05M) | ($112.65M) | ($97.93M) | ($86.26M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($11.52M) | - | - | - |
| Investing Cash Flow | - | - | $8.10M | - | - | - |
| Financing Cash Flow | - | - | $454.0K | - | - | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -9.0% | -7.0% | -7.7% | - | -4.9% | -10.3% |
| Return on equity | -9.7% | -7.3% | -8.2% | - | -5.1% | 12.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 13.16 | 21.95 | 16.16 | 21.93 | 26.33 | 12.92 |
| Quick ratio | 13.16 | 21.95 | 16.16 | 21.93 | 26.33 | 12.92 |
| Cash ratio | 0.53 | 2.60 | 0.64 | 1.11 | 9.56 | 3.01 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.08 | 1.05 | 1.06 | 1.05 | 1.04 | -1.24 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -49.7% | -250.1% | - | - | - | - |
| Net income growth (YoY) | -43.8% | -56.0% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -24.4% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Imago BioSciences against the 5 most active filers in the same SIC group.